Finance & Capital Markets

  1. Biotech Cash Management With Allan Shaw 8/2/2023

    It’s been said that clinical trials are where emerging biotechs go to die. If the science doesn't kill quickly, poor cash management will slowly. On this week's episode of the Business of Biotech, our favored biotech finance management maven, Allan Shaw, offers pointed advice on stretching cash runways for the long run.

  2. Fiscal Turnarounds With Protalix's Eyal Rubin 8/30/2023

    Within about five minutes of conversation with Protalix CFO Eyal Rubin, I learned that he doesn’t bite his tongue about the rigors of biotech business and finance management, which is precisely why I’m eager to talk with him on today’s episode of the podcast. From commercialization deals with big pharma to being about $50 million underwater to swatting away the day trading armchair quarterbacks on Stocktwits, Rubin’s seen a few things and he’s developed more than a few opinions.

  3. Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie 4/24/2025

    On this episode of the Business of Biotech, host Ben Comer speaks with Brian Lortie, President and CEO of Uniquity Bio, about his "no jerk" policy and how his experience building teams at GSK, Endo Pharmaceuticals, and Onspira Therapeutics informs his leadership at Uniquity, a clinical-stage immunology startup backed by Blackstone Life Sciences.

  4. Building A Biotech Hub With Intellia Therapeutics' John Leonard, M.D. 1/13/2024

    We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics.

  5. Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier 11/5/2025

    On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. 

  6. Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD 6/28/2023

    Ahmed Hamdy, MD didn’t ask to be the subject of Nathan Vardi's new book​ For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug. In fact, he’d rather not relive that chapter.

  7. Biotech Funding And IPO Temperature Check With CREATE Medicine's Allan Shaw 11/13/2025

    Allan Shaw, Chief Financial Officer and Chief Business Officer at CREATE Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market.

  8. From Bayer To Startup Bio With AltruBio's Dr. Judy Chou 9/20/2021

    Judy Chou, Ph.D. was a big-pharma MVP. She earned her academic stripes in the hallowed halls of Yale, the Max Planck Institute, and Harvard Medical School before taking on principal scientist roles at AbbVie, Pfizer, and Genentech. That experience parlayed into SVP positions at Tanvex, Medvation, back to Pfizer, and on to Bayer, where she was most recently SVP and Global Head of Biotech before taking the leap into the startup scene as President & CEO at AltruBio in 2020. On today's episode of the Business of Biotech, Dr. Chou shares personal and professional insight into how she's applied what she learned in Big Bio to transform a clinical-stage developer of mAbs designed to treat a broad range of immunological diseases.

  9. The Year's Top Stories With Allan Shaw 12/26/2021

    Join your host Matt Pillar and guest Allan Shaw for a no-holds-barred retrospective on the year's top stories and trends. From the frontlines of the COVID-19 pandemic to the questionable approval of Aduhelm to leadership instability at the FDA and more, Shaw dissects the year past and predicts how those stories will influence the biotech industry in 2022 and beyond.

  10. IL-2 Program Profits With Bonum's Drs. John Mulligan And Neela Patel 12/13/2023

    On this week's episode of the Business of Biotech, we welcome two extraordinary guests - Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics. Together, Neela and John will pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, which was fueled by a high-profile asset sale to Roche.